{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["[177Lu]Lu-DPI-4452"],["[68Ga]Ga-DPI-4452"]],"indication":"unresectable locally advanced or metastatic solid tumors","name":"NCT05706129","nct_id":"NCT05706129","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05706129. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive \\[68Ga\\]Ga-DPI-4452, a single dose on Day 1.","label":"Part A: [68Ga]Ga-DPI-4452","type":"EXPERIMENTAL"},{"description":"Participants will receive a single dose of \\[68Ga\\]Ga-DPI-4452, at screening then escalating doses of \\[177Lu\\]Lu-DPI-4452, on Day 1 of each (Q4W or Q6W) cycle and RP2D will be determined.","label":"Part B: [177Lu]Lu-DPI-4452","type":"EXPERIMENTAL"},{"description":"Participants will receive a single dose of \\[68Ga\\]Ga-DPI-4452, at screening and RP2D dose of \\[177Lu\\]Lu-DPI-4452, on Day 1 of each cycle (Q4W or Q6W) the treatment period.","label":"Part C: [177Lu]Lu-DPI-4452","type":"EXPERIMENTAL"},{"description":"Participants will receive \\[68Ga\\]Ga-DPI-4452, a single dose on Day 1.","label":"Part D: [68Ga]Ga-DPI-4452","type":"EXPERIMENTAL"},{"description":"Participants will receive \\[68Ga\\]Ga-DPI-4452, a single dose on Day 1.","label":"Part E: [68Ga]Ga-DPI-4452","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-03","type":"ESTIMATED"},"conditions":["Clear Cell Renal Cell Cancer (ccRCC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Colorectal Cancer (CRC)","Urothelial Carcinoma (UC)","Indeterminate Renal Mass (IDRM)","Muscle Invasive Bladder Cancer (MIBC)","Head and Neck Cancer (H&N)","Triple Negative Breast Cancer (TNBC)","Squamous Non-Small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":270,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"[68Ga]Ga-DPI-4452","otherNames":[],"type":"DRUG"},{"name":"[177Lu]Lu-DPI-4452","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-11","lead_sponsor":"Lumara Bio Oncologics GmbH","official_title":"A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to Day 7"},{"measure":"Part B: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)","timeFrame":"Cycle 1(each cycle = 28 or 42 days depending on every 4 weeks or 6 weeks dosing schedule)"},{"measure":"Part C: Objective Response Rate (ORR)","timeFrame":"Up to 81 months"},{"measure":"Part D: Concordance Between [68Ga]Ga-DPI-4452 Uptake by PET Imaging and Assessment of Histological Characteristics of IDRM","timeFrame":"Day 1"},{"measure":"Part E: Radiotracer Uptake at Lesion Level Identified by PET Imaging","timeFrame":"Day 1"}],"references":[],"start_date":{"date":"2023-03-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05706129"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05706129"}